We recently talked with Sam Howard, one of the 2022 Jane Calmes ALS Scholarship recipients, to learn more about his personal connection to ALS, what receiving the scholarship means to him, and his future plans in computer science.
The ALS Association spent over $2 million helping fund the development and clinical trial of AMX0035. When the results of that trial showed it was safe and effective in treating ALS, the ALS Association led an advocacy campaign to push the FDA to approve the drug. After two years of advocacy, the FDA finally approved AMX0035.
Most songwriters will tell you, the key to a really good song is the lyrics, a story being told with unique chords and melodies, evoking a specific emotion and compelling listeners to connect and share. No one knows this better than the Swope family, sharing their beautiful memories and storytelling through music, rhythm and song.
We recently talked with Ashley Wong, one of the 2022 scholarship recipients, to learn more about her personal connection to ALS, what receiving the scholarship means to her, and her future plans in healthcare.
As ALS progresses, the challenges of maintaining good nutrition as well as avoiding malnutrition change. With the support of caregivers and a multidisciplinary care team, these challenges can be managed to provide both the best nutrition and best quality of life at all stages.
The ALS Association, the country’s largest nonprofit committed to making ALS livable and finding a cure, today celebrated the Food and Drug Administration’s (FDA) approval of AMX0035, a new treatment for people living with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. The Association invested $2.2 million of funds raised through the 2014 ALS Ice Bucket Challenge into the development and trial of AMX0035, and led the years-long advocacy campaign that pushed the FDA to approve the treatment prior to completion of an ongoing phase 3 trial.
We recently talked with Liam Rudin, one of the 2022 The Jane Calmes ALS Scholarship recipients, to learn more about his connection to ALS, what receiving the scholarship means to him, and his future plans studying accounting.
Earlier this week, The ALS Association filed comments with the Centers for Medicare and Medicaid Services (CMS), urging the agency to provide Medicare coverage for seat elevation systems in power wheelchairs since these systems are a medical necessity for people living with ALS.
We strongly disagree with ICER’s final report on new ALS drugs, which may result in people living with ALS being unable to access life-extending treatments. ICER’s flawed conclusions were based on their discriminatory methodology, as the National Council on Disability has documented.